IPX203の市場規模、予測、新薬の考察（2032年）

薬剤のサマリー

IPX203は、カルビドパ/レボドパ徐放性カプセルの新経口製剤で、パーキンソン病治療薬として開発されました。IPX203は、速放性顆粒と徐放性ビーズを含有しています。速放性顆粒はカルビドパとレボドパからなり、速やかな溶出を可能にするために崩壊性ポリマーが配合されています。徐放性ビーズはレボドパからなり、徐放性ポリマーでコーティングして薬剤をゆっくり放出させ、粘着性ポリマーで吸収部位に長く付着させ、腸溶性コーティングで胃内で早期に崩壊するのを防ぎます。

フェーズ3臨床試験のトップライン結果に基づき、Amneal Pharmaceuticalsはパーキンソン病治療向けIPX203徐放カプセルの新薬承認申請を行い、FDAに受理されました。

当レポートでは、主要7市場（米国・ドイツ・フランス・イタリア・スペイン・英国・日本）におけるパーキンソン病向けIPX203について調査分析し、作用機序、用法と用量、研究開発活動についての考察、収益の予測などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 パーキンソン病におけるIPX203の概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品プロファイル

第3章 競合情勢（上市済みの治療法）

第4章 競合情勢（後期の新治療法）

第5章 IPX203市場の評価

• パーキンソン病におけるIPX203の市場見通し
• 主要7市場の分析
  • 主要7市場のパーキンソン病向けIPX203の市場規模
• 市場の分析：国別
  • 米国のパーキンソン病向けIPX203の市場規模
  • ドイツのパーキンソン病向けIPX203の市場規模
  • 英国のパーキンソン病向けIPX203の市場規模

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: IPX203, Clinical Trial Description, 2023
• Table 2: IPX203, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Late-stage Emerging Therapies)
• Table 5: IPX203 Market Size in the 7MM, in USD million (2019-2032)
• Table 6: IPX203 Market Size in the US, in USD million (2019-2032)
• Table 7: IPX203 Market Size in Germany, in USD million (2019-2032)
• Table 8: IPX203 Market Size in France, in USD million (2019-2032)
• Table 9: IPX203 Market Size in Italy, in USD million (2019-2032)
• Table 10: IPX203 Market Size in Spain, in USD million (2019-2032)
• Table 11: IPX203 Market Size in the UK, in USD million (2019-2032)
• Table 12: IPX203 Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: IPX203 Market Size in the 7MM, USD million (2019-2032)
• Figure 2: IPX203 Market Size in the United States, USD million (2019-2032)
• Figure 3: IPX203 Market Size in Germany, USD million (2019-2032)
• Figure 4: IPX203 Market Size in France, USD million (2019-2032)
• Figure 5: IPX203 Market Size in Italy, USD million (2019-2032)
• Figure 6: IPX203 Market Size in Spain, USD million (2019-2032)
• Figure 7: IPX203 Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: IPX203 Market Size in Japan, USD million (2019-2032)

"IPX203 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about IPX203 for Parkinson's disease in the seven major markets. A detailed picture of the IPX203 for Parkinson's Disease in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the IPX203 for Parkinson's Disease. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the IPX203 market forecast analysis for Parkinson's disease in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Parkinson's disease.

Drug Summary:

IPX203 is a novel, oral formulation of carbidopa/levodopa extended-release capsules designed for the treatment of Parkinson's disease. IPX203 contains immediate-release granules and extended-release beads. The immediate-release granules consist of carbidopa and levodopa, with a disintegrant polymer to allow for rapid dissolution. The extended-release beads consist of levodopa, coated with a sustained release polymer to allow for slow release of the drug, a mucoadhesive polymer to keep the granules adhered to the area of absorption longer, and an enteric coating to prevent the granules from disintegrating prematurely in the stomach.

Based on the topline results from the Phase III clinical trial Amneal Pharmaceuticals submitted an NDA for IPX203 extended-release capsules for the treatment of Parkinson's disease which is accepted by the FDA.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the IPX203 description, mechanism of action, dosage and administration, research and development activities in Parkinson's disease.
• Elaborated details on IPX203 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the IPX203 research and development activities in Parkinson's disease across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around IPX203.
• The report contains forecasted sales of IPX203 for Parkinson's disease till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Parkinson's disease.
• The report also features the SWOT analysis with analyst views for IPX203 in Parkinson's disease.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

IPX203 Analytical Perspective by DelveInsight

• In-depth IPX203 Market Assessment

This report provides a detailed market assessment of IPX203 for Parkinson's disease in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.

• IPX203 Clinical Assessment

The report provides the clinical trials information of IPX203 for Parkinson's disease covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for Parkinson's disease is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence IPX203 dominance.
• Other emerging products for Parkinson's disease are expected to give tough market competition to IPX203 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of IPX203 in Parkinson's disease.
• Our in-depth analysis of the forecasted sales data of IPX203 from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the IPX203 in Parkinson's disease.

Key Questions:

• What is the product type, route of administration and mechanism of action of IPX203?
• What is the clinical trial status of the study related to IPX203 in Parkinson's disease and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the IPX203 development?
• What are the key designations that have been granted to IPX203 for Parkinson's disease?
• What is the forecasted market scenario of IPX203 for Parkinson's disease?
• What are the forecasted sales of IPX203 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to IPX203 for Parkinson's disease?
• Which are the late-stage emerging therapies under development for the treatment of Parkinson's disease?

Table of Contents

1. Report Introduction

2. IPX203 Overview in Parkinson's disease

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and Efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. IPX203 Market Assessment

• 5.1. Market Outlook of IPX203 in Parkinson's disease
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of IPX203 in the 7MM for Parkinson's disease
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of IPX203 in the United States for Parkinson's disease
  • 5.3.2. Market Size of IPX203 in Germany for Parkinson's disease
  • 5.3.3. Market Size of IPX203 in France for Parkinson's disease
  • 5.3.4. Market Size of IPX203 in Italy for Parkinson's disease
  • 5.3.5. Market Size of IPX203 in Spain for Parkinson's disease
  • 5.3.6. Market Size of IPX203 in the United Kingdom for Parkinson's disease
  • 5.3.7. Market Size of IPX203 in Japan for Parkinson's disease

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options